André Uddin

Research Capital Corporation

Image: André Uddin

Andre Uddin is managing director, healthcare research at Mackie Research. Uddin has over 20 years of global experience in the investment, biotechnology and pharmaceutical industries, most recently as strategic advisor and consultant to a number of leading TSX and LSE companies. He was also Vice-President of Strategic Development for a NASDAQ-listed biopharmaceutical company. Uddin began his career in the brokerage community, where he was a top-ranked analyst specializing in coverage of the Canadian biotechnology, pharmaceutical and medical device sectors at National Bank Financial, Research Capital and Merrill Lynch Canada. Uddin holds an Honours Bachelor of Science in Biochemistry from the University of Toronto, and a Ph.D in Biological Chemistry from McGill University. Uddin's bio-organic research has been widely published in many scientific journals, including the Journal of American Chemical Society, Biochemistry and Nucleic Acid Research.

Recent Articles

Study Review Shows Greater Promise for Biopharma Co.'s Cough Treatment 08/01/2022

After Algernon Pharmaceuticals Inc.'s Ifenprodil treatment for chronic cough was reviewed in a Phase 2 analysis, analysts at Research Capital Corp. noted that it is maintaining its Speculative Buy rating on the company.


Recent Quotes

"It would be logical for AGN to develop ifenprodil for two indications."

— André Uddin, Research Capital Corporation (7/28/22)
more >

"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

— André Uddin, Research Capital Corporation (7/18/22)
more >

"AGN's current valuation is favorable from a risk-reward standpoint."

— André Uddin, Research Capital Corporation (1/28/22)
more >

"AGN's risk/reward profile is attractive."

— André Uddin, Research Capital Corporation (12/6/21)
more >

"AGN is switching focus to the IPF/chronic cough indication."

— André Uddin, Research Capital Corporation (8/4/21)
more >

"AGN requested a meeting with the FDA to discuss advancing ifenprodil."

— André Uddin, Research Capital Corporation (5/10/21)
more >

"Final results from AGN's Phase 2b COVID-19 trial are expected soon."

— André Uddin, Research Capital Corporation (3/1/21)
more >

"AGN is to continue a number of preclinical studies of DMT for stroke."

— André Uddin, Research Capital Corporation (2/2/21)
more >

more comments

"AGN remains a high risk, high reward investment opportunity."

— André Uddin, Research Capital Corporation (12/15/20)
more >

fewer comments


Due to permission requirements, not all quotes are shown.